Abstract
One of the challenges inherent in treating adolescent patients is applying the developmental considerations of pediatrics to the treatment of clinical issues studied primarily in adult women. One of the areas where this challenge has been evident is in understanding the effect of hormonal contraceptives on bone health—a topic which remains controversial despite the high volume of research being conducted in this area. In this edition of the Journal, authors Rome and colleagues add to the growing body of knowledge on this topic. Using biochemical markers of bone formation and resorption, they present data suggesting that bone metabolism may be suppressed in 12 to 18-year-old young women using depot medroxyprogesterone acetate (DMPA) or a combined oral contraceptive (COC) containing 20 mcg of ethinyl estradiol and 100 mcg of levonorgestrel. 1 Rome E. Ziegler J. Secic M. et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol. 2004; 17: 6 Abstract Full Text Full Text PDF Scopus (40) Google Scholar
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
